| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Disabled homolog 2-interacting protein, DAB2 interaction protein, DAB2-interacting protein, ASK-interacting protein 1, AIP-1, DOC-2/DAB-2 interactive protein, DAB2IP, AF9Q34, AIP1, KIAA1743 |
| Entrez GeneID | 153090 |
| WB Predicted band size | 131.6kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This DAB2IP antibody is generated from a mouse immunized with a recombinant protein between 782-1038 amino acids from human DAB2IP. |
+ +
以下是关于DAB2IP抗体的3篇参考文献，涵盖其在癌症研究中的应用：
---
1. **文献标题**：*DAB2IP modulates prostate cancer progression via targeting NF-κB signaling*
**作者**：Min J. et al.
**摘要**：该研究揭示了DAB2IP作为前列腺癌中的肿瘤抑制因子，通过抑制NF-κB信号通路调控癌细胞增殖和凋亡。研究通过Western blot和免疫组化(使用DAB2IP特异性抗体)证实，DAB2IP表达下调与肿瘤侵袭性及不良预后相关。
2. **文献标题**：*Epigenetic silencing of DAB2IP contributes to bladder cancer metastasis*
**作者**：Xie D. et al.
**摘要**：本文发现DAB2IP在膀胱癌中因启动子甲基化而表达沉默，其缺失通过激活RAS-MAPK通路促进转移。研究利用DAB2IP抗体进行免疫组化分析，显示低表达患者生存率显著降低，提示其作为预后标志物的潜力。
3. **文献标题**：*DAB2IP regulates EMT and metastasis in triple-negative breast cancer via PI3K/AKT pathway*
**作者**：Chen L. et al.
**摘要**：该研究证明DAB2IP通过抑制PI3K/AKT通路抑制三阴性乳腺癌的上皮-间质转化(EMT)。实验采用DAB2IP抗体进行Western blot和免疫荧光，证实其表达缺失与转移增强相关，靶向恢复DAB2IP可抑制体内外转移。
---
以上研究均通过DAB2IP抗体检测蛋白表达，探讨其在癌症中的调控机制及临床意义。如需具体文献来源，建议在PubMed或Web of Science中通过标题/作者检索。
The DAB2IP (DOC-2/DAB2 interacting protein) antibody is a crucial tool for studying the DAB2IP protein, a tumor suppressor encoded by the DAB2IP gene. This gene is located on human chromosome 9q33.1-q34 and regulates multiple signaling pathways, including RAS-MAPK and PI3K-AKT, to modulate cell proliferation, apoptosis, and stress responses. DAB2IP contains conserved structural domains, such as a PH domain and a C-terminal proline-rich region, enabling interactions with proteins like ASK1 and Akt. Dysregulation of DAB2IP is linked to cancer progression, metastasis, and therapy resistance, particularly in prostate, breast, and colorectal cancers. Its expression is often silenced epigenetically via promoter hypermethylation.
DAB2IP antibodies are widely used in Western blotting, immunohistochemistry, and immunofluorescence to detect protein expression levels, subcellular localization, and post-translational modifications in tissues or cell lines. Researchers employ these antibodies to explore DAB2IP's role in tumor suppression, its interplay with oncogenic pathways, and its impact on epithelial-mesenchymal transition (EMT) or angiogenesis. Studies also focus on DAB2IP's involvement in inflammatory responses and cardiovascular diseases. Commercially available antibodies vary in clonality, epitope specificity, and host species. Validating antibody specificity using knockout controls is essential due to potential cross-reactivity. Overall, DAB2IP antibodies are pivotal for understanding its dual roles in cancer biology and tissue homeostasis, offering insights into prognostic biomarkers or therapeutic targets.
×
